Verseon (LSE:VERS) Debt-to-Revenue : N/A (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Verseon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2019 was £0.30 Mil. Verseon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2019 was £21.46 Mil. Verseon's annualized Revenue for the quarter that ended in Jun. 2019 was £0.00 Mil.

Verseon Debt-to-Revenue Historical Data

The historical data trend for Verseon's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Debt-to-Revenue Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Debt-to-Revenue	Get a 7-Day Free Trial									N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Verseon's Debt-to-Revenue

For the Biotechnology subindustry, Verseon's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verseon's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verseon's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Verseon's Debt-to-Revenue falls into.

Verseon Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Verseon's Debt-to-Revenue for the fiscal year that ended in Dec. 2018 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.295	+	20.891)	/	N/A
	=	N/A

Verseon's annualized Debt-to-Revenue for the quarter that ended in Jun. 2019 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.3	+	21.462)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2019) Revenue data.

Verseon Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Verseon's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.